BRIP1 Antikörper (C-Term)

Produktnummer ABIN965699

Der Kaninchen Polyklonal Anti-BRIP1 Antikörper wurde für IHC validiert. Er ist geeignet, BRIP1 in Proben von Human zu detektieren. Es sind 2+ Publikationen verfügbar.

Kurzübersicht für BRIP1 Antikörper (C-Term) (ABIN965699)

Target: BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1))

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser BRIP1 Antikörper ist unkonjugiert

Applikation: Immunohistochemistry (IHC)

Produktdetails anti-BRIP1 Antikörper

Bindungsspezifität: C-Term

Immunogen: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human BRIP1(ATP-dependent RNA helicase)

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Lagerung: 4 °C

Referenzen für anti-BRIP1 Antikörper (ABIN965699)

Cantor, Drapkin, Zhang, Lin, Han, Pamidi, Livingston: "The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 8, pp. 2357-62, (2004) (PubMed).

Yu, Chini, He, Mer, Chen: "The BRCT domain is a phospho-protein binding domain." in: Science (New York, N.Y.), Vol. 302, Issue 5645, pp. 639-42, (2003) (PubMed).

Details zu BRIP1

Target: BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1))

Andere Bezeichnung: BRIP1

Hintergrund: BRIP1(ATP-dependent RNA helicase Is a DNA-dependent ATPase and 5' to 3' DNA helicase which is required for the maintenance of chromosomal stability. BRIP1 acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. BRIP1 is involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1. BRIP1 binds directly to the BRCT domains of BRCA1. BRIP1 is ubiquitously expressed, with highest levels in testis. Defects in BRIP1 are a cause of susceptibility to breast cancer (BC). BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage), and defective DNA repair.
Synonyms: FACJ (Fanconi anemia group J protein), BRCA1(interacting protein C-terminal helicase 1)

Pathways: DNA Reparatur